COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

Announcement of Zixin Pharmaceutical on the dissolution of shareholder equity pledge and the agreement on repurchase securities

Page view

Stock code: 002118 Securities abbreviation: Zixin Pharmaceutical Announcement No.: 2013-028

Jilin Zixin Pharmaceutical Co., Ltd.

About the dissolution of shareholder equity pledge and the agreement of repurchase securities trading, pledged repo transactions


The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.


I. The pledge of shareholder equity pledge
Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “the company”) recently received the notice from the company’s largest shareholder, Dunhua Kangping Investment Co., Ltd. (hereinafter referred to as “Kangping Company”), and Kangping Company will pledge to Xinyu Ninghang Investment. The management center (limited partnership) of the company sold 14,670,000 shares of unrestricted shares in the process of pledge, and 10,250,000 shares of which were agreed to repurchase securities transactions, and 4,420,000 shares were stock pledge repo transactions.
The above stock pledge company was published on Securities Times, China Securities Journal, Shanghai Securities News, Securities Daily and on July 18, 2012. Announcement No. -025.
Second, the agreement on the purchase of securities transactions
1. The situation of shareholders making purchase-return transactions

transaction hour

Original shareholder involved in the transaction

Securities company involved in the transaction

Number of securities (shares)

Repurchase period (days)

July 11, 2013

Kangping Company

Haitong Securities Co., Ltd.




2. Shareholders hold shareholdings before and after the agreed repurchase transaction


Shareholder name

Nature of shares

Holding shares before the transaction

Holding shares after the transaction

Number of shares

Proportion of total share capital

Number of shares

Proportion of total share capital

Kangping Company

Unrestricted shares






3. Other related instructions

(1) The transaction is in compliance with the “Guiding Opinions on the Transfer of Stocks of the Listed Companies to Release the Stocks” and the relevant laws, regulations, rules and business rules of the Shenzhen Stock Exchange “Agreement on the purchase and return of securities transactions and registration and settlement”.


(2) This transaction is the financing behavior of Kangping Company. During the period of repurchase, the shares of the shareholders of the company, the proposal, the voting and other shareholders or holders’ rights corresponding to the target shares shall be in accordance with the opinions of Kangping Company. exercise.


(3) During the period of repurchase, the relevant equity (including cash dividend, bond redemption principal interest, share issue, transfer of shares, etc.) generated by the underlying shares is attributable to Kangping Company.


(4) During the period of repurchase, Kangping Company may purchase it in advance, except in the cases of laws and regulations, departmental rules, exchange business rules and agreements.


(5) If the repurchase period expires, if Kangping Company defaults, Haitong Securities Co., Ltd. shall dispose of the underlying shares in accordance with the relevant provisions of the “Agreement on Repurchase Securities Trading and Registration and Settlement Business Measures”.


3. Pledged repo transactions

Kangping Company handled 4,420,000 shares of the company (accounting for 0.86% of the company's total share capital) on July 11, 2013 with Haitong Securities Co., Ltd. for stock pledged repo, and the repo transaction date was 2014. January 17th.

As of July 15, 2013, Kangping currently holds a total of 251,475,016 shares of the company. Among them, 10,250,000 shares (accounting for 2% of the company's total share capital) were engaged in an agreed repurchase transaction, and the unrestricted shares were pledge pledge 235,870,000 shares (accounting for 45.98% of the company's total share capital).


Special announcement.

Jilin Zixin Pharmaceutical Co., Ltd. Board of Directors

July 16, 2013